KPX Lifescience.Co.Ltd (114450) - Cash Flow Conversion Efficiency
Based on the latest financial reports, KPX Lifescience.Co.Ltd (114450) has a cash flow conversion efficiency ratio of 0.095x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.33 Billion ≈ $2.26 Million USD) by net assets (₩35.13 Billion ≈ $23.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
KPX Lifescience.Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how KPX Lifescience.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of KPX Lifescience.Co.Ltd for a breakdown of total debt and financial obligations.
KPX Lifescience.Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KPX Lifescience.Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
International Public Partnership
LSE:INPP
|
0.025x |
|
Shaftesbury Capital PLC
LSE:SHC
|
0.010x |
|
BPL Limited
NSE:BPL
|
0.003x |
|
Andromeda Metals Ltd
AU:ADN
|
-0.013x |
|
DIAMINES AND CHEMICALS ORD (BSE)
NSE:DIAMINESQ
|
-0.046x |
|
SOTKAMO SILVER AB NAM.
F:VSO
|
N/A |
|
Karolinska Development AB ser. B
ST:KDEV
|
-0.005x |
|
Xavis Co. Ltd
KQ:254120
|
0.045x |
Annual Cash Flow Conversion Efficiency for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of KPX Lifescience.Co.Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see how much is KPX Lifescience.Co.Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩35.75 Billion ≈ $24.23 Million |
₩525.49 Million ≈ $356.12K |
0.015x | +42.84% |
| 2023-12-31 | ₩35.95 Billion ≈ $24.37 Million |
₩370.02 Million ≈ $250.76K |
0.010x | +111.90% |
| 2022-12-31 | ₩52.64 Billion ≈ $35.67 Million |
₩-4.55 Billion ≈ $-3.08 Million |
-0.086x | -896.27% |
| 2021-12-31 | ₩56.30 Billion ≈ $38.15 Million |
₩611.38 Million ≈ $414.33K |
0.011x | -66.11% |
| 2020-12-31 | ₩59.37 Billion ≈ $40.23 Million |
₩1.90 Billion ≈ $1.29 Million |
0.032x | -54.41% |
| 2019-12-31 | ₩60.36 Billion ≈ $40.90 Million |
₩4.24 Billion ≈ $2.87 Million |
0.070x | -22.75% |
| 2018-12-31 | ₩59.11 Billion ≈ $40.06 Million |
₩5.38 Billion ≈ $3.64 Million |
0.091x | -0.57% |
| 2017-12-31 | ₩62.09 Billion ≈ $42.08 Million |
₩5.68 Billion ≈ $3.85 Million |
0.091x | -20.17% |
| 2016-12-31 | ₩61.66 Billion ≈ $41.79 Million |
₩7.07 Billion ≈ $4.79 Million |
0.115x | +16.09% |
| 2015-12-31 | ₩56.90 Billion ≈ $38.56 Million |
₩5.62 Billion ≈ $3.81 Million |
0.099x | +24.53% |
| 2014-12-31 | ₩51.53 Billion ≈ $34.92 Million |
₩4.09 Billion ≈ $2.77 Million |
0.079x | -- |
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more